Security Snapshot

KAZIA THERAPEUTICS LTD - American Depositary Shares, each representing five-hundred Ordinary Shares (KZIA) Institutional Ownership

CUSIP: 48669G303

13F Institutional Holders and Ownership History from Q2 2025 to Q3 2026

13F reference period

Q2 2026

Institutions Reporting

35

Shares (Excl. Options)

3.64MFull value: 3,639,328 · shares · 30 Jun 2026

Price

$14.08

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / American Depositary Shares, each representing five-hundred Ordinary Shares
Symbol
KZIA on Nasdaq
All holders as of 30 Jun 2026
Q2 2026
Total 13F shares
3,639,328
Latest holder snapshot 5 signals
Total 13F value
$50,726,823
Portfolio coverage rank
0%
Share change
+1,856,459
Value change
+$28,686,466
Number of holders
35
Issuer context Names, identifiers, and filing context for this profile. 2 identity fields
Shares outstanding
11,750,571
SEC-reported price per share
$8.81
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • KZIA - KAZIA THERAPEUTICS LTD - American Depositary Shares, each representing five-hundred Ordinary Shares is tracked under CUSIP 48669G303.
  • 35 institutions reported positions in Q2 2026.
  • 2 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 23 to 35 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from
    $13.05MFull value: $13,047,820 · USD · 31 Mar 2026
    to
    $50.73MFull value: $50,726,823 · USD · 30 Jun 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 35 institutions filings for Q2 2026.

Open SEC evidence

Security key

48669G303

13F reference period

Q2 2026

13F holders

35

13D/G owners

2

CIK / CUSIP context first

Open Q2 2026 holders KZIA full holder history KAZIA THERAPEUTICS LTD SEC filings KAZIA THERAPEUTICS LTD company facts KAZIA THERAPEUTICS LTD insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
2
Security
KZIA
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Lynwood Capital Management Inc. 4.6% -16% $3,601,084,995 -$584,614,620 264,980,500 -14% Lynwood Capital Management Inc. 30 Jun 2026
Ikarian Capital, LLC 4.9% -4% $7,824,823 -$67,624 575,778 -0.86% Ikarian Capital, LLC 30 Jun 2026
As of 30 Jun 2026, 35 institutional investors reported holding
3.64MFull value: 3,639,328 · shares · 30 Jun 2026
shares of KAZIA THERAPEUTICS LTD - American Depositary Shares, each representing five-hundred Ordinary Shares (KZIA). This represents 31% of the company’s total
11.75MFull value: 11,750,571 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
31%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Boxer Capital Management, LLC 4.8% 560,000 0.59% $7,884,800
FLPUTNAM INVESTMENT MANAGEMENT CO 3.5% 414,958 +191% 0.07% $5,842,609
Bleichroeder LP 3.4% 400,000 0% 1% $5,632,000
Ikarian Capital, LLC 3.4% 396,201 0.92% $5,578,510
Dauntless Investment Group, LLC 3% 354,208 +344% 8.6% $4,987,249
Stonepine Capital Management, LLC 2.9% 345,179 0% 3.7% $4,860,120
Point72 Asset Management, L.P. 1.7% 200,300 +0.15% 0% $2,304,224
Ensign Peak Advisors, Inc 0.94% 110,778 0% $1,559,754
MILLENNIUM MANAGEMENT LLC 0.86% 101,376 0% $1,427,374
UBS Group AG 0.69% 81,090 +482% 0% $1,141,748
J. Goldman & Co LP 0.58% 68,491 0.03% $964,353
ADAR1 Capital Management, LLC 0.52% 61,550 0.04% $866,624
JANE STREET GROUP, LLC 0.49% 57,140 0% $804,531
BARCLAYS PLC 0.49% 56,999 +138% 0% $802,546
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.43% 50,616 0% $712,673
COOPERMAN LEON G 0.43% 50,000 0.02% $704,000
Westside Investment Management, Inc. 0.4% 47,585 -5.6% 0.09% $669,997
MORGAN STANLEY 0.4% 46,606 +4561% 0% $656,212
MARSHALL WACE, LLP 0.38% 44,231 0% $622,772
XTX Topco Ltd 0.27% 31,186 0.01% $439,099
BNP PARIBAS FINANCIAL MARKETS 0.26% 30,090 0% 0% $423,667
CITADEL ADVISORS LLC 0.24% 28,509 0% $401,407
RAYMOND JAMES FINANCIAL INC 0.19% 22,599 +43% 0% $318,194
Sequoia Financial Advisors, LLC 0.17% 20,003 -67% 0% $281,643
Engineers Gate Manager LP 0.13% 14,975 0% $210,848

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
6
Headline period
Q2 2026
Rows shown
1-6 of 6
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 109,136 $1,046,207 +$691,902 $9.60 5
2026 Q2 3,639,328 $50,726,823 +$28,686,466 $14.08 35
2026 Q1 1,753,860 $13,047,820 -$4,850,511 $7.44 23
2025 Q4 2,479,478 $17,070,899 +$14,797,378 $6.89 22
2025 Q3 158,075 $1,139,856 +$101,771 $7.21 11
2025 Q2 144,017 $902,466 +$902,466 $6.27 10
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .